Welcome to our dedicated page for Cryoport SEC filings (Ticker: CYRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cryoport, Inc. filings document the regulatory record for a Nasdaq-listed Nevada corporation providing temperature-controlled supply chain solutions to life sciences customers. Recent Form 8-K reports furnish quarterly and annual results releases, while definitive proxy materials describe governance matters, stockholder voting items and business updates tied to Life Sciences Services and Life Sciences Products.
The filing record also identifies Cryoport's registered common stock and recurring disclosure subjects such as operating performance, commercial and clinical cell and gene therapy support, biostorage and bioservices activity, cryogenic systems demand, executive and board governance, and stockholder meeting materials.
Cryoport, Inc. is asking stockholders to approve six director nominees, ratify Deloitte & Touche as auditor, approve executive pay on an advisory basis, and amend its 2018 Omnibus Equity Incentive Plan to add 4,275,000 shares and extend the plan to the tenth anniversary of the 2026 meeting.
In 2025, Cryoport generated $176.2 million in revenue, up 12% year over year. Commercial Cell & Gene Therapy revenue rose to $33.4 million and clinical trial revenue to $47.1 million, while Life Sciences Services reached $96.5 million, about 55% of total revenue. Management forecasts 2026 revenue of $190–$194 million and highlights a growing pipeline of expected therapy approvals and regulatory filings.
Cryoport, Inc. President and CEO Jerrell Shelton exercised stock options and increased his direct share ownership. On the transaction date, he exercised options to purchase 50,000 shares of common stock at an exercise price of $1.87 per share, receiving 50,000 common shares.
Following the transactions, Shelton directly held 1,126,607 shares of Cryoport common stock and 104,007 options to purchase common stock. The exercised options were part of a grant that vested in equal 1/48 installments each month over forty-eight months beginning on May 6, 2016, with the options expiring on May 6, 2026.
CryoPort Inc — Schedule 13G/A (Amendment No. 7): The Vanguard Group reports zero shares beneficially owned of CryoPort Inc common stock, representing 0% of the class. The filing explains an internal realignment at The Vanguard Group on January 12, 2026, after which certain subsidiaries now report holdings separately.
Cryoport, Inc. Chief Financial Officer Robert Stefanovich reported a small, tax-related share sale. On this Form 4, he sold 1,094 shares of common stock at $8.18 per share, with a footnote stating the shares were required to be sold under company policy to pay taxes due upon the vesting of restricted stock rights. After the transaction, he directly holds 279,277 shares, indicating this was a routine withholding event tied to equity compensation rather than a discretionary reduction of his overall stake.
Cryoport, Inc. President and CEO Jerrell Shelton exercised stock options and completed a small share sale. He exercised options to acquire 25,000 shares of common stock at an exercise price of $1.87 per share. On the same date, he sold 2,894 shares of common stock at $8.18 per share.
According to the disclosure, the sold shares were required to be sold under company policies to pay taxes due upon the vesting of restricted stock rights, making this a tax-driven, rather than discretionary, sale. After these transactions, Shelton directly owned 1,076,607 shares of Cryoport common stock.
Cryoport, Inc. Chief Scientific Officer Mark W. Sawicki reported an automatic sale of 1,341 shares of common stock at $8.18 per share. According to the disclosure, the shares were required to be sold under company policies to pay taxes due upon the vesting of restricted stock rights. Following this transaction, Sawicki directly holds 102,356 shares of Cryoport common stock.
Cryoport, Inc. officer Edward J. Zecchini reported routine equity compensation activity and a small share sale. He received 21,322 shares of Common Stock as restricted stock rights that vest in four equal annual installments beginning March 14, 2027, and a stock option grant for 63,965 shares at an exercise price of $8.60 per share expiring in 2033. On March 16, 2026, he sold 2,014 shares of Common Stock at $8.00 per share, with a footnote explaining the shares were required to be sold to pay taxes due on the vesting of restricted stock rights. After these transactions, he directly holds 109,719 shares of Common Stock.
Cryoport, Inc. President and CEO Jerrell Shelton reported two transactions. He sold 7,918 shares of Common Stock at $8.00 per share on March 16, 2026, with a footnote stating the shares were required to be sold to pay taxes due on vesting of restricted stock rights. After this tax-related sale, he directly owned 1,054,501 Common shares. On March 14, 2026, he also received a grant of 492,901 stock options with an exercise price of $8.60 per share, expiring on March 14, 2033; 1/48 of these options vest on the 14th of each month over 48 months beginning April 14, 2026.
Cryoport, Inc. Chief Scientific Officer Mark W. Sawicki reported a mix of equity awards and a small sale of common stock. He received 22,845 shares of common stock as restricted stock rights that vest in four equal annual installments beginning on March 14, 2027. He was also granted stock options for 68,534 shares at an exercise price of $8.60 per share, vesting 1/48 each month starting April 14, 2026, through forty-eight months.
On March 16, 2026, Sawicki sold 3,235 shares of common stock at $8.00 per share, which the company notes were required to be sold to pay taxes due upon vesting of restricted stock rights. After this tax-related sale, he directly holds 103,697 shares of Cryoport common stock, along with the newly granted stock options.
Cryoport, Inc. Chief Financial Officer Robert Stefanovich reported a mix of equity compensation grants, option exercises, and tax-driven share sales. He exercised options for 87,188 shares of Common Stock at $1.87 per share and sold 38,700 shares on the same day at a weighted average price of $7.7619. According to the footnotes, the sale proceeds were used to pay the option exercise price and related withholding taxes, making this largely a liquidity and tax event rather than a pure discretionary sale.
On a later date, he sold an additional 2,743 shares at $8.00 per share, which the company’s policies required to cover taxes due on vesting restricted stock rights. He also received 27,413 restricted stock rights that will vest in four equal annual installments beginning March 14, 2027, and a stock option grant for 82,240 shares at an exercise price of $8.60 per share, expiring in 2033. After these transactions, Stefanovich directly holds 280,371 shares of Cryoport common stock, so the 41,443 shares sold represent a minority portion of his overall equity position.